D
Dina Y. Gewaily
Researcher at University of Pennsylvania
Publications - 10
Citations - 1311
Dina Y. Gewaily is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Randomized controlled trial & Retinal degeneration. The author has an hindex of 8, co-authored 10 publications receiving 918 citations. Previous affiliations of Dina Y. Gewaily include Scheie Eye Institute.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial
Stephen R. Russell,Jean Bennett,Jennifer Wellman,Daniel C. Chung,Zi Fan Yu,Amy Tillman,Janet Wittes,Julie Pappas,Okan U. Elci,Sarah McCague,Dominique Cross,Kathleen A. Marshall,Jean Walshire,Taylor Kehoe,Hannah Reichert,Maria C. Davis,Leslie Raffini,Lindsey A. George,F. Parker Hudson,Laura E. Dingfield,Xiaosong Zhu,Julia A. Haller,Elliott H. Sohn,Vinit B. Mahajan,Wanda Pfeifer,Michelle T. Weckmann,Chris A. Johnson,Dina Y. Gewaily,Arlene V. Drack,Edwin M. Stone,Katie Wachtel,Francesca Simonelli,Bart P. Leroy,Bart P. Leroy,J. Fraser Wright,Katherine A. High,Albert M. Maguire +36 more
TL;DR: Voretigene neparvovec gene replacement improved functional vision in RPE65-mediated inherited retinal dystrophy previously medically untreatable.
Journal ArticleDOI
RPGR-Associated Retinal Degeneration in Human X-Linked RP and a Murine Model
Wei Chieh Huang,Alan F. Wright,Alejandro J. Roman,Artur V. Cideciyan,Forbes D C Manson,Dina Y. Gewaily,Sharon B. Schwartz,Sam Sadigh,Maria P. Limberis,Peter Bell,James M. Wilson,Anand Swaroop,Samuel G. Jacobson +12 more
TL;DR: The natural history in this model will permit preclinical proof-of-concept studies to be designed and such studies should advance progress toward human therapy, and knowledge of the patterns should guide treatment strategies.
Journal ArticleDOI
Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion.
TL;DR: A qualitative assessment of the results from GENEVA indicated that the dexamethasone implant was not associated with improvement in visual acuity after six months among participants with CRVO-ME, and the effectiveness and safety of intravitreal steroids in the treatment of CR VO-ME was explored.
Journal ArticleDOI
Obstructive sleep apnea and central serous chorioretinopathy
Frank L. Brodie,Emily S. Charlson,Tomas S. Aleman,Rebecca Salvo,Dina Y. Gewaily,Marisa K. Lau,Neil D. Farren,Stephanie B Engelhard,Maxwell Pistilli,Alexander J. Brucker +9 more
TL;DR: Patients with CSCR did not have statistically significant higher rates of OSA risk or previous diagnosis when compared with matched controls, which contrasts with previous work showing a strong association between the diseases.
Journal ArticleDOI
Remission of Intermediate Uveitis: Incidence and Predictive Factors
John H. Kempen,Dina Y. Gewaily,Craig Newcomb,Teresa L. Liesegang,R. Oktay Kaçmaz,Grace A. Levy-Clarke,Robert B. Nussenblatt,James T. Rosenbaum,H. Nida Sen,Eric B. Suhler,Jennifer E. Thorne,C. Stephen Foster,Douglas A. Jabs,Abhishek R. Payal,Tonetta D Fitzgerald +14 more
TL;DR: The results suggest that intermediate uveitis is a chronic disease with an overall low rate of remission and pars plana vitrectomy was associated with increased probability of remission.